AR085800A1 - Vacuna de rinitis equina - Google Patents
Vacuna de rinitis equinaInfo
- Publication number
- AR085800A1 AR085800A1 ARP120100823A ARP120100823A AR085800A1 AR 085800 A1 AR085800 A1 AR 085800A1 AR P120100823 A ARP120100823 A AR P120100823A AR P120100823 A ARP120100823 A AR P120100823A AR 085800 A1 AR085800 A1 AR 085800A1
- Authority
- AR
- Argentina
- Prior art keywords
- strain
- identity
- erav
- equine
- erab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Composiciones inmunogénicas contra virus de rinitis equina, en particular virus de rinitis equina A y B y métodos para su uso y su preparación. Las composiciones inmunogénicas, en formas de realización alternativas, también incluyen otros agentes patógenos de equinos.Reivindicación 1: Una composición inmunogénica caracterizada porque comprende una o varias cepas de inactivados o vivos, atenuados el virus de rinitis equina A (ERAV) o virus de rinitis equina B (ERBV), a) en donde la cepa de ERAV o la cepa de ERAB, antes de la inactivación o atenuación, causa una enfermedad respiratoria detectable en al menos el 50% de caballos seronegativos expuestos a la cepa; y/o b) crecidos en cultivo celular a 106 TCID50/mL o más; y/o, c) cuando se usa como una vacuna en equinos en una dosis de 106 TCID50 o más da como resultado una titulación sérica de al menos 1:112; y/o d) en donde dicha cepa de ERAV comprende una secuencia genómica cuyo transcripto inverso tiene más del 95% de identidad con la SEQ ID Nº 2; y/o e) en donde dicho ERAV codifica una poliproteína con una secuencia de aminoácidos con más del 95% de identidad con la SEQ ID Nº 3; y/o f) en donde dicha cepa de ERBV comprende una secuencia genómica cuyo transcripto inverso tiene más del 95% de identidad con el transcripto inverso de la secuencia genómica de la cepa de ERAB que tiene número de acceso ATCC PTA-11829; y/o g) en donde dicha cepa de ERVB codifica una poliproteína con una secuencia de aminoácidos con más del 95% de identidad con la poliproteína codificada por el genoma de la cepa de ERAB que tiene número de acceso ATCC PTA-11829.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452390P | 2011-03-14 | 2011-03-14 | |
| US201161510226P | 2011-07-21 | 2011-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085800A1 true AR085800A1 (es) | 2013-10-30 |
Family
ID=45876924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100823A Pending AR085800A1 (es) | 2011-03-14 | 2012-03-13 | Vacuna de rinitis equina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9187730B2 (es) |
| EP (2) | EP2686012B1 (es) |
| AR (1) | AR085800A1 (es) |
| AU (2) | AU2012229192B2 (es) |
| BR (2) | BR122019023542B1 (es) |
| CA (2) | CA3018230A1 (es) |
| ES (2) | ES2748555T3 (es) |
| MA (1) | MA35303B1 (es) |
| MX (1) | MX350718B (es) |
| NZ (1) | NZ614147A (es) |
| TW (1) | TW201300537A (es) |
| WO (1) | WO2012125525A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2748555T3 (es) | 2011-03-14 | 2020-03-17 | Boehringer Ingelheim Animal Health Usa Inc | Vacuna contra la rinitis equina |
| CA2967532A1 (en) | 2014-11-24 | 2016-06-02 | Intervet International B.V. | Inactivated equine influenza virus vaccines |
| US10064930B2 (en) * | 2015-01-16 | 2018-09-04 | Boehringer-Ingelheim Vermedica, Inc. | Immunogenic compositions and methods for pigeon fever |
| JP7354106B2 (ja) * | 2017-12-04 | 2023-10-02 | インターベット インターナショナル ベー． フェー． | レプリコン粒子および油性アジュバントによるワクチン接種 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2702373B1 (fr) | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
| AUPN720195A0 (en) | 1995-12-18 | 1996-01-18 | University Of Melbourne, The | Equine rhinovirus 1 proteins |
| US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| US6177082B1 (en) | 1998-08-13 | 2001-01-23 | The University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Cold-adapted equine influenza viruses |
| US7425437B2 (en) | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| IL153020A0 (en) | 2000-05-26 | 2003-06-24 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| WO2002067899A1 (en) | 2001-02-28 | 2002-09-06 | Akzo Nobel N.V. | Injectable water-in-oil emulsions |
| WO2002072036A2 (en) | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
| US20030104008A1 (en) | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
| AUPR472501A0 (en) | 2001-05-02 | 2001-05-24 | Council Of The Queensland Institute Of Medical Research, The | Equine rhinitis a virus antigens |
| NZ570270A (en) | 2001-07-27 | 2010-08-27 | Wyeth Corp | West nile vaccine for equidae |
| ATE359816T1 (de) | 2001-10-19 | 2007-05-15 | Acambis Inc | Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren |
| WO2004045529A2 (en) | 2002-11-15 | 2004-06-03 | Acambis, Inc. | West nile virus vaccine |
| CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| EP1664786B1 (en) | 2003-09-09 | 2014-11-12 | Idexx Laboratories, Inc. | Detection of west nile virus infection and vaccination |
| US7459163B2 (en) | 2004-02-25 | 2008-12-02 | University Of Kansas | Infectious DNA as a vaccine against west nile and other flaviviruses |
| EP1773403B1 (en) | 2004-07-09 | 2018-04-25 | The University of North Carolina At Chapel Hill | Alphavirus-based adjuvants |
| CA2582534A1 (en) | 2004-09-09 | 2006-03-16 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
| EP1645283A1 (en) | 2004-10-08 | 2006-04-12 | Chiron Behring GmbH & Co. KG | Combination vaccine |
| AU2005318171B2 (en) | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| EP1896069B1 (en) | 2005-06-24 | 2013-03-13 | Intervet International BV | Inactivated chimeric vaccines and related methods of use |
| US7425336B2 (en) | 2005-08-25 | 2008-09-16 | Mevial Limited | Canine influenza vaccines |
| US7384642B2 (en) | 2005-08-25 | 2008-06-10 | Merial Limited | Canine influenza vaccines |
| RU2396976C2 (ru) | 2005-10-07 | 2010-08-20 | Пфайзер Продактс Инк. | Вакцины и способы лечения собачьего гриппа |
| US7468187B2 (en) | 2005-10-18 | 2008-12-23 | Iowa State University Research Foundation, Inc. | Canine influenza virus and related compositions and methods of use |
| BRPI0618041A2 (pt) | 2005-11-01 | 2011-08-16 | Intervet Int Bv | uso de um vìrus inativado da influenza eqüina, e, método para a proteção de eqüinos contra a infecção com influenza eqüina |
| US7455842B2 (en) | 2005-12-05 | 2008-11-25 | University Of Kansas | Chimeric West Nile viruses and uses thereof |
| KR100850545B1 (ko) | 2007-10-30 | 2008-08-05 | 주식회사 에니멀제네틱스 | 신규한 개 인플루엔자 바이러스 및 이의 백신 |
| US8821889B2 (en) | 2008-08-29 | 2014-09-02 | Boehringer Ingelheim Vetmedica, Inc. | West Nile Virus vaccine |
| ES2748555T3 (es) | 2011-03-14 | 2020-03-17 | Boehringer Ingelheim Animal Health Usa Inc | Vacuna contra la rinitis equina |
-
2012
- 2012-03-12 ES ES14164842T patent/ES2748555T3/es active Active
- 2012-03-12 NZ NZ614147A patent/NZ614147A/en not_active IP Right Cessation
- 2012-03-12 WO PCT/US2012/028706 patent/WO2012125525A2/en active Application Filing
- 2012-03-12 ES ES12710420T patent/ES2842595T3/es active Active
- 2012-03-12 BR BR122019023542-2A patent/BR122019023542B1/pt active IP Right Grant
- 2012-03-12 EP EP12710420.6A patent/EP2686012B1/en active Active
- 2012-03-12 US US13/417,855 patent/US9187730B2/en active Active
- 2012-03-12 EP EP14164842.8A patent/EP2772266B1/en active Active
- 2012-03-12 CA CA3018230A patent/CA3018230A1/en active Pending
- 2012-03-12 CA CA2829226A patent/CA2829226C/en active Active
- 2012-03-12 MX MX2013010125A patent/MX350718B/es active IP Right Grant
- 2012-03-12 AU AU2012229192A patent/AU2012229192B2/en active Active
- 2012-03-12 BR BR112013023354-0A patent/BR112013023354B1/pt not_active IP Right Cessation
- 2012-03-13 TW TW101108504A patent/TW201300537A/zh unknown
- 2012-03-13 AR ARP120100823A patent/AR085800A1/es active Pending
-
2013
- 2013-09-12 MA MA36241A patent/MA35303B1/fr unknown
-
2017
- 2017-03-06 AU AU2017201526A patent/AU2017201526C1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA35303B1 (fr) | 2014-08-01 |
| AU2017201526B2 (en) | 2019-07-18 |
| AU2012229192B2 (en) | 2017-04-20 |
| BR122019023542B1 (pt) | 2022-02-15 |
| MX350718B (es) | 2017-09-14 |
| EP2686012A2 (en) | 2014-01-22 |
| AU2017201526A1 (en) | 2017-03-30 |
| EP2772266B1 (en) | 2019-07-31 |
| AU2017201526C1 (en) | 2019-10-24 |
| WO2012125525A2 (en) | 2012-09-20 |
| NZ708320A (en) | 2016-08-26 |
| EP2686012B1 (en) | 2020-12-02 |
| ES2842595T3 (es) | 2021-07-14 |
| ES2748555T3 (es) | 2020-03-17 |
| US20120237543A1 (en) | 2012-09-20 |
| NZ614147A (en) | 2015-08-28 |
| EP2772266A1 (en) | 2014-09-03 |
| US9187730B2 (en) | 2015-11-17 |
| TW201300537A (zh) | 2013-01-01 |
| CA2829226C (en) | 2023-01-03 |
| MX2013010125A (es) | 2013-10-07 |
| BR112013023354A2 (pt) | 2016-12-06 |
| BR112013023354B1 (pt) | 2022-02-15 |
| AU2012229192A1 (en) | 2013-08-29 |
| CA2829226A1 (en) | 2012-09-20 |
| CA3018230A1 (en) | 2012-09-20 |
| WO2012125525A3 (en) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| AR065076A1 (es) | Vacuna contra el papilomavirus | |
| CL2016000240A1 (es) | Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal. | |
| MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
| Chen et al. | Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement | |
| ES2663872T3 (es) | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria | |
| WO2008039408A3 (en) | Live bacterial vaccines for viral infection prophylaxis or treatment | |
| MY163972A (en) | Attenuated recombinant newcastle disease virus and vaccine containing the same | |
| MX2009006178A (es) | Vacuna contra salmonela. | |
| UY32274A (es) | Pestivirus quimericos | |
| AR106026A1 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
| PE20121685A1 (es) | Antigeno ndv recombinante y usos del mismo | |
| PE20140871A1 (es) | COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA | |
| CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
| WO2017156511A8 (en) | Live attenuated zika virus vaccine | |
| CO2019013220A2 (es) | Virus oncolíticos y método | |
| AR085800A1 (es) | Vacuna de rinitis equina | |
| CO7461133A2 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| AR103427A1 (es) | Vacuna contra la fiebre aftosa | |
| CO6280408A2 (es) | Vacuna de virus de la lengua azul y composiciones inmunogenicas procedimientos de uso y procedimeintos de la produccuion de la misma | |
| AR129904A2 (es) | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagación incrementada en las células | |
| AR094810A1 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| AR081409A1 (es) | PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) | |
| Swati et al. | Isolation and phylogenetic characterization of Canine distemper virus from India | |
| CL2023002187A1 (es) | Virus para vacuna contra el síndrome respiratorio y reproductivo porcino |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |